These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18945509)

  • 61. Mortality risk among sulfonylureas: a systematic review and network meta-analysis.
    Simpson SH; Lee J; Choi S; Vandermeer B; Abdelmoneim AS; Featherstone TR
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):43-51. PubMed ID: 25466239
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry.
    Yang X; So WY; Ma RC; Yu LW; Ko GT; Kong AP; Ng VW; Luk AO; Ozaki R; Tong PC; Chow CC; Chan JC
    Diabetes Res Clin Pract; 2010 Dec; 90(3):343-51. PubMed ID: 20889221
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Timing of administration of sulfonyl urea derivatives].
    de Smet PA; Fischer HR
    Ned Tijdschr Geneeskd; 2000 Jun; 144(25):1206-9. PubMed ID: 10897299
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Diabetes, coronary heart disease and sulphonylureas-not the final word.
    Betteridge DJ; Close L
    Eur Heart J; 2000 May; 21(10):790-2. PubMed ID: 10781346
    [No Abstract]   [Full Text] [Related]  

  • 65. Glimepiride-induced vasculitis: a case report.
    Ben Salem C; Hmouda H; Bouraoui K
    Br J Clin Pharmacol; 2007 Jul; 64(1):113-4. PubMed ID: 17324240
    [No Abstract]   [Full Text] [Related]  

  • 66. Permanent neonatal diabetes mellitus caused by a novel homozygous (T168A) glucokinase (GCK) mutation: initial response to oral sulphonylurea therapy.
    Turkkahraman D; Bircan I; Tribble ND; Akçurin S; Ellard S; Gloyn AL
    J Pediatr; 2008 Jul; 153(1):122-6. PubMed ID: 18571549
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Glyburide and glipizide.
    Med Lett Drugs Ther; 1984 Aug; 26(669):79-80. PubMed ID: 6433158
    [No Abstract]   [Full Text] [Related]  

  • 68. Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes.
    Räkel A; Renier G; Roussin A; Buithieu J; Mamputu JC; Serri O
    Diabetes Obes Metab; 2007 Jan; 9(1):127-9. PubMed ID: 17199728
    [No Abstract]   [Full Text] [Related]  

  • 69. [Coronary artery disease in diabetic patients].
    Henry P
    Rev Prat; 2008 Sep; 58(14):1561-4. PubMed ID: 18839684
    [TBL] [Abstract][Full Text] [Related]  

  • 70. New perspectives in noninsulin-dependent diabetes mellitus and the role of glipizide in its treatment. Proceedings of a symposium.
    Am J Med; 1983 Nov; 75(5B):1-99. PubMed ID: 6673593
    [No Abstract]   [Full Text] [Related]  

  • 71. Glibenclamide-induced cholestasis.
    Tholakanahalli VN; Potti A; Heyworth MF
    West J Med; 1998 Apr; 168(4):274-7. PubMed ID: 9584675
    [No Abstract]   [Full Text] [Related]  

  • 72. Cardiovascular prevention in high-risk patients with type 2 diabetes mellitus: when to start it?
    Garcia RG; López-Jaramillo P
    Eur Heart J; 2008 Aug; 29(16):2058; author reply 2058-9. PubMed ID: 18559403
    [No Abstract]   [Full Text] [Related]  

  • 73. Effects of first and second generation sulphonylureas on cardiotoxicity of strophanthidin in rabbits.
    Ballagi-Pordány G; Köszeghy A; Koltai MZ; Aranyi Z; Pogátsa G
    Diabetes Res; 1989 Dec; 12(4):193-7. PubMed ID: 2637095
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Assessment of coronary artery disease in patients with (a)symptomatic diabetes.
    Bax JJ; van der Wall EE
    Eur Heart J; 2006 Mar; 27(6):631-2. PubMed ID: 16497691
    [No Abstract]   [Full Text] [Related]  

  • 75. The protein tyrosine phosphatase receptor type f (PTPRF) locus is associated with coronary artery disease in type 2 diabetes.
    Menzaghi C; Paroni G; De Bonis C; Coco A; Vigna C; Miscio G; Lanna P; Tassi V; Bacci S; Trischitta V
    J Intern Med; 2008 Jun; 263(6):653-4. PubMed ID: 18298487
    [No Abstract]   [Full Text] [Related]  

  • 76. Heeding clues to metformin-associated lactic acidosis: prompt response can save life.
    Kumar U; Chennavir B; Gopi A
    Emerg Med J; 2008 Aug; 25(8):537-8. PubMed ID: 18660415
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Glibenclamide-induced hypoglycemic coma in 51 older patients with type 2 diabetes mellitus.
    Ben-Ami H; Nagachandran P; Mendelson A; Edoute Y
    J Am Geriatr Soc; 1999 May; 47(5):631-3. PubMed ID: 10323665
    [No Abstract]   [Full Text] [Related]  

  • 78. NMR-based prediction of cardiovascular risk in diabetes.
    Roussel R; Mentré F; Bouchemal N; Hadjadj S; Lièvre M; Chatellier G; Menard J; Panhard X; Le Hénanff A; Marre M; Le Moyec L;
    Nat Med; 2007 Apr; 13(4):399-400. PubMed ID: 17415367
    [No Abstract]   [Full Text] [Related]  

  • 79. Comment on Hong et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes care 2013;36:1304-1311.
    Lund SS; Gong Y
    Diabetes Care; 2014; 37(1):e19-20. PubMed ID: 24356605
    [No Abstract]   [Full Text] [Related]  

  • 80. Response to comment on Hong et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes care 2013;36:1304-1311.
    Hong J; Zhang Y; Lai S; Ning G
    Diabetes Care; 2014; 37(1):e21. PubMed ID: 24356606
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.